TACE联合放疗对原发性大肝癌患者血清肿瘤标志物及恶性分子表达的影响

Effect of TACE combined with radiotherapy on expression of serum tumor markers and malignant molecules in patients with primary large liver cancer

目的:探讨TACE联合放疗对原发性大肝癌患者血清肿瘤标志物及恶性分子表达的影响。方法:选择在本院进行治疗的原发性大肝癌患者90例,回顾性分析研究对象的治疗方案并分为:接受放疗的对照组51例、接受TACE联合放疗的TACE组39例。对比两组治疗前后血清肿瘤标志物、血管新生指标、凋亡分子表达水平的差异。结果:治疗前,两组血清肿瘤标志物、血管新生指标、凋亡分子表达水平比较,差异无统计学意义(P>0.05)。治疗后,TACE组血清中肿瘤标志物AFP、AFu、CGT、CEA、CA19-9的水平低于对照组;血清中血管新生指标HGF、VEGF、MMP-9、EGFR的水平低于对照组;血清中凋亡分子Bax、Caspase-4、Caspase10的水平高于对照组,Bcl-2、Survivin的水平低于对照组(P<0.05)。结论:原发性大肝癌患者在放疗基础上加入TACE治疗,可进一步降低肿瘤恶性程度。

Objective:To investigate the effect of TACE combined with radiotherapy on the expression of serum tumor markers and malignant molecules in patients with primary large liver cancer.Methods:A total of 90 patients with primary large liver cancer who were treated in our hospital between September 2016 and September 2018 were retrospectively analyzed and divided into the control group(n=51)who received radiotherapy and the TACE group(n=39)who received TACE combined with radiotherapy.The expression levels of serum tumor markers,angiogenesis indexes and apoptotic molecules were compared between the two groups before and after treatment.Results:Before treatment,there were no statistically significant differences in the expression levels of serum tumor markers,angiogenesis indexes or apoptotic molecules between the two groups(P>0.05).After treatment,the serum levels of tumor markers AFP,AFu,CGT,CEA and CA19-9 in the TACE group were significantly lower than those in the control group(P<0.05);the serum levels of angiogenesis indexes HGF,VEGF,MMP-9 and EGFR were significantly lower than those in the control group(P<0.05);the serum levels of apoptotic molecules Bax,Caspase-4 and Caspase-10 were significantly higher than those in the control group(P<0.05),while the levels of Bcl-2 and Survivin were significantly lower than those in the control group(P<0.05).Conclusion:TACE on the basis of radiotherapy can further reduce the tumor malignancy in primary large liver cancer patients.